A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

• Participant has active moderate to severe atopic dermatitis (AD) defined by EczemaArea and Severity Index (EASI) ≥ 16, Investigator's Global Assessment (IGA) ≥ 3, ≥ 10%body surface area (BSA) of AD involvement at the Screening and Baseline Visits, andBaseline weekly average of daily Worst Pruritus NRS ≥ 4.
• Participant is a candidate for systemic therapy or have recently required systemictherapy for AD.

Exclusion Criteria:

• Participant has prior exposure to Janus Kinase (JAK) inhibitor.
• Participant has prior exposure to dupilumab.
• Participant is unable or unwilling to discontinue current AD treatments prior to thestudy.
• Participant has requirement of prohibited medications during the study.
• Participant has other active skin diseases or skin infections requiring systemictreatment or would interfere with appropriate assessment of AD lesions.
• Female participant who is pregnant, breastfeeding, or considering pregnancy during thestudy.